冠状动脉钙化和心脏辐射剂量对局部晚期非小细胞肺癌总生存期的综合影响:减少心脏辐射剂量对谁最有利?

IF 3.3 3区 医学 Q2 ONCOLOGY
Yui Watanabe, Yutaro Koide, Hidetoshi Shimizu, Takahiro Aoyama, Yurika Shindo, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira
{"title":"冠状动脉钙化和心脏辐射剂量对局部晚期非小细胞肺癌总生存期的综合影响:减少心脏辐射剂量对谁最有利?","authors":"Yui Watanabe, Yutaro Koide, Hidetoshi Shimizu, Takahiro Aoyama, Yurika Shindo, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira","doi":"10.1016/j.cllc.2025.05.002","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Despite advances in treatment for unresectable locally advanced non-small cell lung cancer (LA-NSCLC), overall survival (OS) remains poor. The effects of coronary artery calcification (CAC) and heart radiation doses on OS in LA-NSCLC patients, especially their combined impact, have not been thoroughly investigated. This study aimed to examine the individual and combined effects of CAC and heart dose on OS in LA-NSCLC patients treated with radiotherapy over a 3-year follow-up period.</p><p><strong>Patients and methods: </strong>The study included 140 patients who received definitive radiotherapy for LA-NSCLC (stage III, 92.1%) from 2015 to 2021. The endpoint was OS, with each patient followed for a fixed 3-year period.</p><p><strong>Results: </strong>Univariate Cox regression analysis identified mean heart dose (MHD; hazard ratio [HR], 4.0 [2.2-7.3]; P < .001) and CAC in multiple vessels (HR, 2.6 [1.5-4.8]; P = .001) as significant predictors of worse OS, both serving as independent predictors of poorer outcomes in multivariate analysis. Kaplan-Meier analysis revealed that combining MHD and CAC in any coronary artery, each specific artery, and multivessels provided enhanced risk stratification for OS (P < .001 for all combinations). Among patients with higher MHD, those with calcification in the left main trunk (LMT) had the highest annual event rate (28.2%), showing a significant difference (P < .001) compared to patients with lower MHD (4.4%).</p><p><strong>Conclusion: </strong>Combination of CAC and heart dose enhanced risk stratification for 3-year OS in LA-NSCLC patients treated with radiotherapy. Importantly, patients with calcification in the LMT derived the greatest benefit from reducing heart doses.</p>","PeriodicalId":10490,"journal":{"name":"Clinical lung cancer","volume":" ","pages":""},"PeriodicalIF":3.3000,"publicationDate":"2025-05-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?\",\"authors\":\"Yui Watanabe, Yutaro Koide, Hidetoshi Shimizu, Takahiro Aoyama, Yurika Shindo, Shingo Hashimoto, Hiroyuki Tachibana, Takeshi Kodaira\",\"doi\":\"10.1016/j.cllc.2025.05.002\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Despite advances in treatment for unresectable locally advanced non-small cell lung cancer (LA-NSCLC), overall survival (OS) remains poor. The effects of coronary artery calcification (CAC) and heart radiation doses on OS in LA-NSCLC patients, especially their combined impact, have not been thoroughly investigated. This study aimed to examine the individual and combined effects of CAC and heart dose on OS in LA-NSCLC patients treated with radiotherapy over a 3-year follow-up period.</p><p><strong>Patients and methods: </strong>The study included 140 patients who received definitive radiotherapy for LA-NSCLC (stage III, 92.1%) from 2015 to 2021. The endpoint was OS, with each patient followed for a fixed 3-year period.</p><p><strong>Results: </strong>Univariate Cox regression analysis identified mean heart dose (MHD; hazard ratio [HR], 4.0 [2.2-7.3]; P < .001) and CAC in multiple vessels (HR, 2.6 [1.5-4.8]; P = .001) as significant predictors of worse OS, both serving as independent predictors of poorer outcomes in multivariate analysis. Kaplan-Meier analysis revealed that combining MHD and CAC in any coronary artery, each specific artery, and multivessels provided enhanced risk stratification for OS (P < .001 for all combinations). Among patients with higher MHD, those with calcification in the left main trunk (LMT) had the highest annual event rate (28.2%), showing a significant difference (P < .001) compared to patients with lower MHD (4.4%).</p><p><strong>Conclusion: </strong>Combination of CAC and heart dose enhanced risk stratification for 3-year OS in LA-NSCLC patients treated with radiotherapy. Importantly, patients with calcification in the LMT derived the greatest benefit from reducing heart doses.</p>\",\"PeriodicalId\":10490,\"journal\":{\"name\":\"Clinical lung cancer\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":3.3000,\"publicationDate\":\"2025-05-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical lung cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2025.05.002\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical lung cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.cllc.2025.05.002","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景:尽管不可切除的局部晚期非小细胞肺癌(LA-NSCLC)的治疗取得了进展,但总生存率(OS)仍然很低。冠状动脉钙化(CAC)和心脏辐射剂量对LA-NSCLC患者OS的影响,特别是它们的联合影响,尚未得到深入的研究。本研究旨在通过为期3年的随访,研究CAC和心脏剂量对接受放疗的LA-NSCLC患者OS的个体和联合影响。患者和方法:该研究纳入了2015年至2021年接受LA-NSCLC (III期,92.1%)最终放疗的140例患者。终点为OS,每位患者随访3年。结果:单因素Cox回归分析确定了平均心脏剂量(MHD;风险比[HR], 4.0 [2.2-7.3];P < 0.001)和多血管CAC (HR, 2.6 [1.5-4.8];P = .001)作为较差OS的显著预测因子,两者在多变量分析中均作为较差预后的独立预测因子。Kaplan-Meier分析显示,在任何冠状动脉、特定动脉和多血管中合并MHD和CAC可增强OS的风险分层(所有组合的P < 0.001)。在MHD较高的患者中,左主干钙化(LMT)的年事件发生率最高(28.2%),与MHD较低的患者(4.4%)相比,差异有统计学意义(P < 0.001)。结论:CAC联合心脏剂量增强了LA-NSCLC放疗患者3年OS的风险分层。重要的是,有钙化的患者从减少心脏剂量中获益最大。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Combined Impact of Coronary Artery Calcification and Heart Radiation Dose on Overall Survival in Locally Advanced Non-Small Cell Lung Cancer: Who Benefits Most from Reducing Heart Radiation Dose?

Background: Despite advances in treatment for unresectable locally advanced non-small cell lung cancer (LA-NSCLC), overall survival (OS) remains poor. The effects of coronary artery calcification (CAC) and heart radiation doses on OS in LA-NSCLC patients, especially their combined impact, have not been thoroughly investigated. This study aimed to examine the individual and combined effects of CAC and heart dose on OS in LA-NSCLC patients treated with radiotherapy over a 3-year follow-up period.

Patients and methods: The study included 140 patients who received definitive radiotherapy for LA-NSCLC (stage III, 92.1%) from 2015 to 2021. The endpoint was OS, with each patient followed for a fixed 3-year period.

Results: Univariate Cox regression analysis identified mean heart dose (MHD; hazard ratio [HR], 4.0 [2.2-7.3]; P < .001) and CAC in multiple vessels (HR, 2.6 [1.5-4.8]; P = .001) as significant predictors of worse OS, both serving as independent predictors of poorer outcomes in multivariate analysis. Kaplan-Meier analysis revealed that combining MHD and CAC in any coronary artery, each specific artery, and multivessels provided enhanced risk stratification for OS (P < .001 for all combinations). Among patients with higher MHD, those with calcification in the left main trunk (LMT) had the highest annual event rate (28.2%), showing a significant difference (P < .001) compared to patients with lower MHD (4.4%).

Conclusion: Combination of CAC and heart dose enhanced risk stratification for 3-year OS in LA-NSCLC patients treated with radiotherapy. Importantly, patients with calcification in the LMT derived the greatest benefit from reducing heart doses.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Clinical lung cancer
Clinical lung cancer 医学-肿瘤学
CiteScore
7.00
自引率
2.80%
发文量
159
审稿时长
24 days
期刊介绍: Clinical Lung Cancer is a peer-reviewed bimonthly journal that publishes original articles describing various aspects of clinical and translational research of lung cancer. Clinical Lung Cancer is devoted to articles on detection, diagnosis, prevention, and treatment of lung cancer. The main emphasis is on recent scientific developments in all areas related to lung cancer. Specific areas of interest include clinical research and mechanistic approaches; drug sensitivity and resistance; gene and antisense therapy; pathology, markers, and prognostic indicators; chemoprevention strategies; multimodality therapy; and integration of various approaches.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信